PROK - prokidney.com Operating income before deduction of amortization

Brandmark of ProKidney Corp (PROK)

ProKidney Corp. (PROK) is developing a cell therapy for kidney regeneration, aiming to replace dialysis with a monopoly product. The base EBITDA reflects the actual cash flow, with the metric holding at 0.00. This unique organ restoration method ensures global market reach. Management is currently focusing on clinical trials and partnerships, which drives the current volatility in investor confidence.

prokidney.com (PROK) - Profit before payment of interest, taxes and amortization from 11/23/2025 to 11/10/2026

ProKidney - analytical breakdowns and key metrics (PROK)

- market price and analyst price targets:
Stock Price ProKidney Pharma|PROK - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization ProKidney|PROK - Enterprise Value
- balance sheet equity data:
Equity per Share ProKidney|PROK - Company Book Value|Capitalization to Book Value Ratio prokidney.com|PROK - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital ProKidney Corp.|PROK - Long-Term Debt to Equity Ratio|Current Liabilities to Capital ProKidney Corp|PROK - Company Debts|Debts to Book Capitalization Ratio ProKidney|PROK - Company Long-Term Debt|Company Short-Term Loans and Borrowings ProKidney|Immediate Liquidity prokidney.com
- earnings and valuation multiples indicators:
PROK - Company Net Income|Projected Future Earnings ProKidney Corp.|PROK - P/E Multiple|Market Cap to Projected Earnings prokidney.com|PROK - PEG Multiple|Enterprise Value to Operating Income Before Depreciation ProKidney|PROK - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months ProKidney|PROK - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months prokidney.com|PROK - Net earnings per share growth this year|Expected net earnings per share growth next year ProKidney Corp.
Analysis of all company metrics:ProKidney Pharma, PROK
Manufactured product of ProKidney Corp.

For ProKidney Corp., which operates in the closed segment of regenerative kidney therapy, operating profit serves as the benchmark for the efficiency of patent implementation. This metric isolates net cash flow from one-time accounting adjustments and depreciation. By analyzing the current EBITDA, an investor filters out speculative noise from actual operational strength. This is critical given the high costs of regulatory control for living medicines. Growth in this indicator confirms the fundamental resilience of the business, excluding debt load.

Competitors of ProKidney Corp. (PROK)

Operating profit EBITDA Travere Corp TVTX|Ardelyx, Inc. - Operating profit EBITDA|Operating income before deduction of amortization akebia.com AKBA|TVRD: Operating profit EBITDA|Operating profit before amortization DMAC|Profit before payment of interest, taxes and amortization Unicycive|Operating profit before amortization RMTI (rockwellmed.com)|Operating profit EBITDA CVKD|CDT - Profit before interest, taxes and amortization|Calliditas Therapeutics AB - Operating profit before deduction of amortization|Renalytix AI (RNLX) - Profit before interest, taxes and amortization|ZVSA - Profit before payment of interest, taxes and amortization